Investor Presentation H1 2023
15
Investor presentation
First six months of 2023
Novo Nordisk has agreed to acquire Inversago Pharma
therapeutic focus
Innovation and
Acquisition of Inversago Pharma supports Novo Nordisk's
aspiration within obesity and other metabolic disorders
Inversago has multiple drug candidates affecting the peripheral
cannabinoid receptors
.
•
•
Further raise the innovation-bar for diabetes
treatment
Develop a leading portfolio of superior treatment
solutions for obesity
•
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases
focusing on CVD, NASH and CKD
CVD: Cardiovascular Disease; CKD: Chronic Kidney Disease; NASH: Non-alcoholic fatty liver disease; CB1: Cannabinoid receptor type 1
Q
D
Novo Nordisk acquired Inversago for up to USD 1.075 billion
Leading candidate INV-202 is an oral CB1 receptor blocker,
for the treatment of obesity, diabetes and complications
associated with metabolic disorders.
INV-202 showed weight loss potential in phase 1
Novo NordiskⓇView entire presentation